Treatment of chronic inflammatory diseases with CM101/GBS toxin
AssigneeVanderbilt University
InventorsCarl G. Hellerqvist, Barbara D. Wamil
Life of this patent
Estimating the term…
Abstract
A method of treating a chronic inflammatory disease such as rheumatoid arthritis or psoriasis includes treating a patient with a toxin derived from Group B β-hemolytic Streptococcus bacteria. The purified GBS toxin, or CM101, may be administered. intravenously to the patient in repeated doses.
Claims25
A method for treating a patient with a chronic inflammatory disease, which method comprises:
- administering to the patient a polysaccharide toxin from Group B β-hemolytic Streptococcus (GBS) bacteria in a quantity sufficient to reduce formation of new blood vessels at a site of disease.
A method for treating a patient having a chronic inflammatory disease that is angiogenesis dependent, which method comprises:
- administering to the patient a compound that reduces formation of new blood vessels at a site of disease but does not inhibit wound healing, wherein the compound is a polysaccharide toxin from Group B β-hemolytic Streptococcus (GBS) bacteria.
The method of claim wherein the GBS toxin provides biological activity as evidenced by induction of respiratory distress in a sheep assay or activation of complement and binding to neovasculature in a peroxidase-antiperoxidase assay of a tumor tissue specimen.
A method for treating psoriasis in the body of a patient, which method comprises:
- administering to the patient a polysaccharide toxin from Group B β-hemolytic Streptococcus (GBS) bacteria in a quantity sufficient to reduce signs or symptoms of psoriasis.
The method of claim 28 wherein the GBS toxin provides biological activity as evidenced by induction of respiratory distress in a sheep assay or activation of complement and binding to neovasculature in a peroxidase-antiperoxidase assay of a tumor tissue specimen.
Dependencies are inferred from the claim text.